Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference (RNAi) and blocking messenger RNA (mRNA) translation. The Company's pipeline includes a clinical program in Familial Adenomatous Polyposis (FAP) and preclinical programs in bladder cancer and myotonic dystrophy. The Company has two liposomal-based delivery platforms. The first platform utilizes amino-based liposomal delivery technology and incorporates a molecule the Company calls DiLA2 (Di-Alkylated Amino Acid). In April 2012, the Company announced the completion of dosing for Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial of CEQ508.